New Study Shows Superior Healing Outcomes Associated with Ultrasonic Debridement

FARMINGDALE, N.Y., July 09, 2018 (GLOBE NEWSWIRE) — Misonix, Inc. (NASDAQ:MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices that enhance clinical outcomes, announced today the results of a new Randomized Controlled Trial (RCT), which demonstrated superior healing outcomes associated with the use of ultrasonic debridement for lower extremity wounds.

The study, “The effect of 22.5kHz low frequency contact ultrasound debridement (LFCUD) on lower extremity wound healing for a vascular surgery population: A Randomized Controlled Trial” – was published in the International Wound Journal, and compared Misonix’s SonicOne® ultrasonic debridement device to standard sharp debridement in a 70 patient study conducted by The Ottawa Hospital: Limb Preservation Program in Ottawa, Canada. It concluded that SonicOne ultrasonic debridement treatment resulted in better wound appearance, significant reduction in wound area and superior healing outcomes, compared to other patients in the study that were not treated with SonicOne.

Stavros Vizirgianakis, President and CEO of Misonix, commented, “We are very proud to partner with world class wound care facilities like The Ottawa Hospital: Limb Preservation Program. These results from their recently published study are important both because of the study’s rigor and its conclusive data, which shows marked improvement in healing rates and effectiveness of our SonicOne ultrasonic technology to positively and significantly impact patients’ lives. Wound treatment is an attractive growth opportunity for Misonix and we are confident that our best-in-class ultrasound wound treatment products will allow us to significantly grow across both existing and new markets and drive added adoption of our therapeutic ultrasonic medical devices, including SonicOne.”

Dr. Christine Murphy, lead author of the study, said, “This detailed work is strong evidence that SonicOne improves tissue quality in a challenging population facing very high risk of amputation, including more wound closures. A Randomized Controlled Trial is level one evidence and not commonly available for wound technologies, and as an assessor-blinded study, this is very powerful.”

About Misonix, Inc.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix’s therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix’s proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company’s web site at

Joe Dwyer Joseph Jaffoni, Norberto Aja, Jennifer Neuman
Chief Financial Officer JCIR
Misonix, Inc. 212-835-8500 or

Paragon 28® launches a cut guide system specifically to control bone resection while addressing IM reduction in a Lapidus procedure

ENGLEWOOD, Colo.July 5, 2018 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation to help streamline medical procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

In a 1st tarsometatarsal (TMT) joint arthrodesis, there is a risk of over shortening the first ray due to over-resection of bone or an inherently short first ray. Attempting to create cuts to achieve the precise amount of IM correction while simultaneously creating congruent surfaces to promote bony apposition at the fusion site can be technically challenging. Avoiding plantar gapping by removing the plantar cartilage from the soft tissue attachments can also prove difficult. Dorsiflexion of the first ray can occur during joint preparation as well, which can lead to transfer metatarsalgia.

The Paragon 28® Lapidus Cut Guide System addresses these concerns by giving the surgeon eight different options for the desired amount of IM correction, while reproducibly guiding cuts through the entirety of the joint resulting in congruent and accurate cartilage removal that minimizes the chance of over-resection. A built in dorsal to plantar taper on cuts made on the metatarsal in two different guide variations is offered to reduce the likelihood of first ray dorsiflexion intraoperatively.

Product Page:

Media Contact:  Jim Edson, Vice President of Marketing and Product Management,

SOURCE Paragon 28

Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

AUDUBON, Pa., July 03, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today the expansion of its orthopedic trauma product portfolio with two new product offerings, the ANTHEM® Ankle Fracture System and the ANTHEM® Proximal Humerus Fracture System, marking the Trauma division’s fourth and fifth comprehensive product launches over the last 10 months.

“This is an exciting time for Globus Trauma as we continue to execute our product launch strategy and build a comprehensive Trauma product portfolio,” said Barclay Davis, Vice President, Orthopedic Trauma. “With each new product introduction, our goal is to design systems that help streamline the procedure, increase versatility, reduce operative time, and improve patient care.”

ANTHEM® Ankle Fracture Plating and other lower extremity systems will be exhibited at the annual American Orthopedic Foot and Ankle Society Meeting in Boston, Massachusetts July 11th-14th.  Globus Medical invites meeting attendees to Booth 206 to experience its recent product innovations and discuss trauma advancements with the company’s product development experts.

  • The ANTHEM® Ankle Fracture System is an extensive range of 7 unique plating options for treatment of virtually any ankle fracture. Over 25% thinner than the market leader’s plate, ANTHEM®’s low profile ankle fracture plates are designed to minimize soft tissue irritation from implant prominence. Anatomically contoured plates, extensive screw options and instruments specifically designed for ankle anatomy are rolled into one efficient and comprehensive system for treating ankle fractures.
  • The ANTHEM® Proximal Humerus Fracture System is designed to treat a wide variety of shoulder fractures and streamline procedural flow. The unique polyaxial screw technology allows for more accurate targeting of dense calcar bone to enhance fixation, independent of plate position. Large suture holes simplify suture attachment for soft tissue or rotator cuff repair. This comprehensive stand-alone system includes small fragment instruments and innovative retractors to help streamline the surgical procedure, aid in visibility of the fracture site, and optimize surgical time.


The ANTHEM™ Fracture System is indicated for fixation of fractures, osteotomies, arthrodesis and reconstruction of bones for the appropriate size of the device to be used in adult patients, including the clavicle, scapula, humerus, radius, ulna, small bones (metacarpals, metatarsals, phalanges), wrist, pelvis, femur, tibia, fibula, ankle, and foot. The clavicle hook plate may be used for dislocations of the acromioclavicular joint.

Small fragment, proximal tibia, clavicle and distal fibula plates may be used in all pediatric subgroups (except neonates) and small stature adults.  Distal radius plates may be used in adolescents (12-21 years of age). Plating may be used in patients with osteopenic bone.

To learn more about the complete line of Globus Medical Trauma products visit

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800

University Hospital Center of Grenoble Alpes (CHUGA) Becomes the 20th University Hospital Equipped with the EOS® System in France

July 03, 2018

PARIS–(BUSINESS WIRE)–Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the installation of its EOS® system at the University Hospital Center of Grenoble Alps (CHUGA), a state-of-the-art hospital facility for osteoarticular surgery in children and adults. CHUGA is the 20th university hospital center to acquire an EOS® system, and the new system will be dedicated to the center’s clinic as well as to clinical research activities.

With more than 2,100 beds, CHUGA employs nearly 8,000 professionals, including 1,700 doctors. It has an advanced technical platform and provides highly specialized care. The center’s teams are recognized for their excellence in orthopedic surgery, particularly in the field of advanced surgical techniques assisted by navigation or robotics.

The new EOS system will be located in the pediatric radiology department within the pediatric section of the hospital. It will be used in the care of both pediatric and adult patients through a collaboration with two adult orthopedic services located in the North and South Poles of CHUGA.

“The EOS system will allow us to further develop the clinical care of our pediatric patients through imaging at low radiation dose. It will also significantly accelerate our collaborative research programs with EOS on the orthopedic treatment of scoliosis with braces,” commented Professor Aurélien Courvoisier, Pediatric Orthopedic Surgeon.

“We are very pleased to serve the Grenoble Hospital Center for clinical and research applications,” commented Marie Meynadier, Chief Executive Officer of EOS imaging. “The patient has always been our main concern as we work to spread low-dose, 2D/3D imaging capabilities. EOS has changed the care of osteo-articular pathologies and has become a standard thanks to lower radiation, higher accuracy, and 3D imaging of the full body, all of them valuable in choosing the most effective treatments, preparing surgical intervention, as well as in post-operative follow-up. On the research side, we hope to open new perspectives on the treatment of spinal deformities with braces, and will also pursue collaborative programs on the integration of the EOS examination data in the operating room.”

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI


EOS imaging
Marie Meynadier, Ph: +33 (0)1 55 25 60 60
Press Relations (US)
Joanna Zimmerman, Ph: 646-536-7006
The Ruth Group
Investor Relations (US)
Matt Picciano / Emma Poalillo
Ph: 646-536-7008 / 7024
The Ruth Group

Orthofix Realigns Business Unit Structure, Names Brad Niemann President of Global Orthofix Spine and Davide Bianchi President of Global Orthofix Extremities

June 25, 2018

LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International N.V., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the realignment of its strategic business units and the promotion of Brad Niemann to President of Global Orthofix Spine, which includes the BioStim, Spine Fixation, Spinal Kinetics and Biologics businesses. The Extremity Fixation business, which will now be referred to as “Orthofix Extremities” will continue to be led globally by Davide Bianchi as the President of Global Orthofix Extremities. This alignment structures Orthofix around two pillars: Spine and Extremities.

“In 2013, Orthofix segmented its business into four strategic business units to gain better strategic and management focus and drive needed performance improvements,” said Orthofix President and Chief Executive Officer, Brad Mason. “This strategy has proved very successful over the last several years and resulted in each business performing well with solid leadership, execution and growth.

“Today we are announcing these organizational changes as part of an overall strategy to position the Company for growth acceleration and to realize opportunities that can only be achieved by leveraging our full portfolio of spine solutions,” Mason continued. “As we expand our product offerings and integrate new technologies, such as the M6® disc, we believe the time is right to further optimize our structure to better serve our surgeon customers through a two-pillar approach of a consolidated Spine group and a focused Extremities business. We are fortunate to have two extremely talented executives to lead these organizations.”

“I am excited to have the opportunity to lead the Spine group and look forward to working more closely with the current management teams from all the spine product areas,” said Brad Niemann, President of Global Orthofix Spine. “This structure will foster better collaboration and alignment by bringing these teams together under one umbrella to help ensure we make the most of our many opportunities in the market.”

Orthofix will continue to report its financial performance according to the current four strategic business unit structure until completion of this transition, which is expected to be at the beginning of 2019. Subsequently, the Company will evaluate what changes in the Company’s segment financial reporting, if any, may be required as a result of this transition. In any event, the Company will continue to provide revenue transparency into the extremities, stimulation, spine hardware, biologics and Spinal Kinetics product groups.

About Brad Niemann

Niemann joined Orthofix in 2012 as Senior Vice President, Commercial Operations and was quickly promoted to President of the BioStim strategic business unit in June 2013 where he has successfully led the efforts to expand the utilization of bone growth stimulation technology. Prior to Orthofix, he worked in a variety of management and leadership roles of increasing responsibility at DJO Global, Inc. including serving as Senior Vice President, Recovery Sciences where he led their commercial efforts. As President of Global Orthofix Spine, he will work with the leaders of the Orthofix spine businesses in the development of strategies and initiatives to advance the Company’s worldwide spine business.

About Orthofix

Orthofix International N.V. is a global medical device company focused on musculoskeletal products and therapies. The Company’s mission is to improve patients’ lives by providing superior reconstruction and regenerative musculoskeletal solutions to physicians worldwide. Headquartered in Lewisville, Texas, Orthofix’s spine and orthopedic extremities products are distributed in over seventy countries via the Company’s sales representatives and distributors. For more information, please visit


Orthofix International N.V.
Investor Relations
Mark Quick, 214-937-2924
Media Relations
Denise Landry, 214-937-2529

Stimwave Appoints Industry Veteran Steven Amelio as Chief Financial Officer

June 19, 2018

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, today announced the appointment of industry veteran Steven Amelio to the position of Chief Financial Officer (CFO).

Amelio is a senior financial executive with 30 years of experience in the medical device industry. Over his 20 year career with United States Surgical Corporation, Tyco Healthcare Group LP and ultimately Covidien, PLC he rose through the finance department in various roles and spent 10 years as Divisional CFO of Surgical Devices. With his broad- based knowledge of the industry and operations, Amelio was involved in all aspects of many acquisitions, divestitures, and purchased technologies in surgical areas such as minimally invasive, electro-surgery, orthopedic, biologics, and other related areas in addition to overseeing global finance organizations.

“Steven’s demonstrated strong healthcare and medical device track record and hands on finance experience make him the perfect fit for Stimwave to enhance our strategic plans,” said Laura Tyler Perryman, co-founder and CEO of Stimwave. “The addition of Steven strengthens our executive management team to support our high growth and to meet the market demand for our innovative and game changing neuromodulation platform technology.”

With 10 years of private equity experience in medical device companies, most recently, Amelio was CFO of Paradigm Spine, LLC, a private equity medical device company located in New York City where he was recognized in Becker’s Spine Review as an Industry Leader to Know. Amelio has an MBA in Finance and a BBA in Accounting from Iona College in New York.

“Stimwave’s technology provides beneficial alternatives to millions of patients suffering from chronic pain annually, as well as the healthcare system overall. I was fortunate to witness the positive impact new technologies have on patients very early in my career at United States Surgical Corporation and look forward to being part of the Stimwave team as we launch and embark on global commercialization and rapid growth,” said Amelio.

Stimwave’s devices use Wireless Pain Relief® technology and are 95 percent smaller than any other neuromodulation device on the market and can be fixated through an injectable method. The device delivers small pulses of energy to specific nerves, triggering a reaction that enables the brain to remap pain pathways, thus providing pain relief. Stimwave is the only neuromodulation device manufacturer cleared by the FDA to help reduce chronic neuropathic pain at most locations throughout the body, from back and leg pain addressed by spinal cord stimulation to PNS treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.

About Stimwave

Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management.

Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes are forward-looking statements. A number of risks and uncertainties such as risks associated with product development and commercialization efforts, expected timing or results of any clinical trials, ultimate clinical outcome and perceived or actual advantages of the Company’s products, market and physician acceptance of the products, intellectual property protection, and competitive offerings could cause actual events to adversely differ from the expectations indicated in these forward looking statements.


Glodow Nead Communications
Rosemary O’Brien and Sarah Rogers, 415-394-6500

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

June 19, 2018

BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. CINGAL has previously been evaluated in a placebo-controlled Phase III clinical trial (13-01) that demonstrated safety and efficacy through 26-weeks. The 16-02 trial compared CINGAL, a combination of cross-linked HA and triamcinolone hexacetonide (TH), with TH alone and cross-linked HA in treating patients with osteoarthritis (OA) in the knee. The primary endpoint was a comparison of the pain reduction of CINGAL compared with TH alone at 26-weeks. While CINGAL achieved greater pain reduction numerically at every time point in the study, the difference at 26-weeks did not reach statistical significance.

The patient response to CINGAL in the study was strong, as significant improvements in pain, function, and quality of life were observed at levels consistent with, and in most cases greater than, the results of the 13-01 placebo-controlled Phase III study of CINGAL. A strong safety profile was also shown, matching previous clinical studies as well as real-world experience from growing product use globally. The duration of pain reduction was also similar to the previous study as patient improvement after CINGAL injection was maintained near peak levels throughout the 26-week duration of the study. Follow-up of patients continues in a prospectively designed extension phase to the study, which will gather data through 39-weeks.

Prof. Laszlo Hangody, MD, Ph.D., DSc., the global principal investigator of several CINGAL trials, said, “While it has been observed that TH has a longer duration of effect than other corticosteroids, the results in this study were surprising. Nevertheless, the patient response to CINGAL in this study was strong as patients received statistically and clinically meaningful rapid and long-lasting improvement in symptoms compared with base-line, consistent with the previous study as well as my experience in my practice. Taken together, the results of the two Phase III studies validate the effectiveness of this novel combination for use in patients with knee osteoarthritis.”

CINGAL is the first and only commercially-available combination viscosupplement, and it is currently being used successfully by physicians to provide rapid and long-lasting relief from pain and discomfort caused by OA for patients in a growing number of countries. CINGAL is a patented formulation composed of the Company’s proprietary cross-linked sodium hyaluronate and triamcinolone hexacetonide. CINGAL is Anika’s third-generation viscosupplement, following the Company’s ORTHOVISC and MONOVISC products, to treat pain associated with osteoarthritis of the knee.

Anika President and CEO Joseph Darling said, “OA patients continue to benefit from the proven safety and efficacy of CINGAL in growing numbers outside of the U.S. where CINGAL is approved. The benefits of combining HA and a corticosteroid are mirrored by physician feedback and real-world experience. While we expected CINGAL to perform as well as it did, we were surprised that the difference in pain reduction seen in this trial did not reach statistically significant levels at six months. We will however, continue to monitor the results of the ongoing 3-month extension study. We are actively reviewing the data and our plan is to work closely with regulators to come to an understanding of the next steps required to gain U.S. regulatory approval of CINGAL. We remain fully committed to bringing this impactful OA solution to U.S. patients and physicians.”

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary HA technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit


Forward-Looking Statements

The statements made in fifth paragraph of this press release as to the future activities and plans of the Company are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements, which reflect the current beliefs and expectations of the Company’s management, may be affected by inaccurate assumptions and by known and unknown risks and uncertainties that are difficult to predict or beyond the Company’s control, including actions and decisions of regulatory authorities. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission and available at www.sec.govForward-looking statements are based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.


For Investor Inquiries: Anika Therapeutics, Inc.
Sylvia Cheung, Chief Financial Officer, 781-457-9000
For Media Inquiries: Pure Communications
Sonal Vasudev, 917-523-1418


EOS imaging Launches New EOSone Private Practice Program

June 15, 2018

PARIS–(BUSINESS WIRE)–EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced the launch of EOSone, its new Private Practice Program, at Becker’s 16th Annual Future of Spine + The Spine, Orthopedic and Pain Management-Driven ASC Conference, being held June 14-16 in Chicago.

The EOSone program is designed to address the unique needs of private practices and to ensure that safe imaging is available to all patients, not just those treated in a traditional hospital environment. The program includes support to assist sites with patient communication and education about low dose, 3D imaging, and patient specific surgical planning with respect to their conditions and treatment plans.

“In the U.S., the private practice sector accounts for 73 percent of all orthopedic practices*, representing a significant opportunity for the EOS technology,” said Marie Meynadier, Chief Executive Officer of EOS imaging. “We launched the EOSone program as an option for private clinics to better inform patients interested in safe and personalized orthopedic care about our EOS platform, 3D models, and surgical planning solutions. We also include in this program customized financing options to facilitate access for private practices to our comprehensive platform.”

Because private practices are often hindered by the initial/upfront investment associated with capital equipment, the EOSone program offers sites various options to match the sites’ estimated volumes, with access to the full suite of EOS products, including 3D services, 3D surgical planning solutions, and system services, training, support, and updates for the duration of the program.

*Becker’s Spine: 11 Statistics and Facts About Orthopedics and Orthopedic Practices

About EOS imaging
EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI


EOS imaging
Marie Meynadier
Ph: +33 (0)1 55 25 60 60
Press Relations (US)
Joanna Zimmerman
The Ruth Group
Ph: 646-536-7006
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024

Tyber Medical Promotes Gary Thomas To Chief Operating Officer And Adds Wesley Johnson As Executive Vice President Of Product Development

BETHLEHEM, Pa.June 12, 2018 /PRNewswire/ — Tyber Medical, LLC, a privately held company focusing on developing innovative medical devices for private label opportunities and advancing the science of bioengineered surfaces, announces the promotion of Gary Thomas to Chief Operating Officer and the addition of Wesley Johnson as Executive Vice President of Product Development.

Gary Thomas has been with Tyber Medical since 2017 as the Executive Vice President of Operations.  As a key member of the leadership team, his direct role is to help Tyber Medical achieve record growth through seamless execution.  He is accountable for the supply chain including customer/project management, information systems, product launches, and innovative driven solutions to optimize operational performance.  Mr. Thomas has over 28 years of experience in operations management, product development, quality, and regulatory areas.  Before joining Tyber Medical, he was the Vice President of Operations for Musculoskeletal Transplant Foundation (MTF), an orthopaedic biologic company. While there, he was responsible for multiple sites (approx. 300 employees) including: Operations, Distribution, Development, Supply Chain, and Business Unit Operations. Prior to MTF, he was the Group Vice President of Portfolio and Project Management at Biomet overseeing spine, bone healing, and microfixation. Mr. Thomas has also held top management positions for Norman Noble, Howmedica (Stryker), and Pfizer.  Mr. Thomas holds a Master’s degree in Management from NJIT and a Bachelor’s in Business Management from Ramapo College.

As the Chief Operating Officer for Tyber Medical Mr. Thomas will be responsible for management and strategic leadership over the company’s day-to-day operations as well as developing future organic operational growth.  He will be directly responsible for the business organization and strategic alignment in Operations, Inventory (SIOP) and Supply Chain Management, Customer Service, Manufacturing, Facilities, IT/Business Systems, and other customer centric services.

Tyber Medical is happy to announce the addition of Wesley Johnson to the management team as Executive Vice President of Product Development.  Mr. Johnson has an extensive background in Product Development and Business Management in the joint reconstruction, spine, trauma, and biologics fields.  Prior to Tyber Medical he was a Vice President of Research & Development at Medacta in Chicago, Illinois.  Other key management roles have included General Manager and Vice President of Arthroplasty Division at Cayenne Medical, Co-founder/President and CEO at Alexandra Research Technologies, Director of Product Development at Spine-Tech (now Zimmer Spine), and Founder of Insight Medical as well as several other management titles.  With Mr. Johnson’s knowledge and expertise, he will lead a team that is responsible for Research, Clinical, Product Development, and innovative customer focused/driven services.  He will provide guidance and mentorship to the engineering team while creating new product innovation, product launches, and product renovations to meet broad business objectives.  Mr. Johnson holds a Bachelor’s of Science Degree and a Master of Science Degree in Mechanical Engineering from the University of Minnesota, Institute of Technology.

Jeff Tyber, CEO and President of Tyber Medical commented, “We are extremely lucky to have Wes and Gary on our leadership team.  As we grow the company, we are building an organization lead by experienced orthopedic leaders to execute our customer centric growth strategies; from creating innovative products which Wes will manage, to stream-lining the production process to deliver consistent reliability and scalability which Gary will continue to oversee.”

Visit Tyber Medical’s Booth #609, at OMTEC in Chicago, IL where the company will showcase innovative products available for private labeling as well as meeting Wesley Johnson, Tyber Medical’s new Executive Vice President of Product Development.

About Tyber Medical, LLC.

Tyber Medical, LLC is an orthopedic device manufacturer providing rapid access to portfolio enhancing, regulatory approved, orthopedic implants within the spine and extremity/trauma markets.  While focusing on rapid product commercialization, the company distributes products via private labeling; releasing 14 spine and 25 extremity/trauma systems since its founding in 2012.  Tyber Medical utilizes the differentiated, bioengineered technology such as TyPEEK® osteoconductive coatings and BioTy™, a new antimicrobial nano-textured surface modification to enhance the company’s growing portfolio.

Eric Dickson
83 South Commerce Way, Suite 310
Bethlehem PA 18017
(610) 849-1710

SOURCE Tyber Medical

Oska® Wellness Wins Another MedTech Breakthrough Award

CARLSBAD, Calif., June 6, 2018 /PRNewswire/ — Oska Wellness, a technology company committed to developing consumer health and wellness products, announced that its Oska Pulse has been selected for the “Best New Technology Solution – Pain Management” award from MedTech Breakthrough, an independent organization that recognizes the top companies, technologies, and products in the global health and medical technology market.  This is the second straight MedTech Breakthrough win for Oska Pulse, which was also selected in 2017 for “Best IoT Healthcare Wearable Device.”

“All of us at Oska are excited to receive this second award from MedTech, who have recognized Oska’s mission to provide non-invasive, drug-free pain management solutions,” said Greg Houlgate, Founder, Chief Business Development and Product Officer for Oska Wellness. “This is an important industry recognition for our young company and our flagship device, Oska Pulse.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Patient Engagement, Electronic Health Records (EHR), mHealth, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,000 nominations from more than 10 countries.

“We are thrilled to recognize Oska Wellness and congratulate them on back-to-back industry recognition for their innovative health tech product, the Oska Pulse,” said James Johnson, managing director, MedTech Breakthrough. “The level of innovation displayed by nominees in the MedTech Breakthrough Awards program is incredibly high and Oska Wellness was able to stand out once again to take home the trophy, a significant achievement for the Company. Congratulations to the entire Oska Wellness team and we look forward to seeing continued innovation and success from them in the future.”